Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics

Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease

Series A-2 led by Hatteras Venture Partners and Biohaven

Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors

NEW HAVEN, Conn., March 1, 2021-- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company has raised $11 million in a Series A-2 financing led by existing investor Hatteras Venture …